Bull
$1,138.36
Scenario price
$1,166.510
-15.865 (-1.36%)At close
Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries.
Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.
BofA
—
2026-10-09
BofA
2026-10-09
Price Target
—
Cantor Fitzgerald
—
2026-10-08
Cantor Fitzgerald
2026-10-08
Price Target
—
Morgan Stanley
—
2026-10-07
Morgan Stanley
2026-10-07
Price Target
—
JPMorgan
—
2026-09-28
JPMorgan
2026-09-28
Price Target
—
Guggenheim
—
2026-09-18
Guggenheim
2026-09-18
Price Target
—
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Eli Lilly's Q3 Earnings Preview Focuses on Key Drug Sales

Eli Lilly Stock Split Prospects Analyzed

Rapid Growth in Cancer Drug Market Forecasted

Analysis of Three High-Growth Dividend Stocks

Investment Choices: Bristol Myers Squibb vs. Eli Lilly
Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.
22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.

Rotation into defensive sectors like healthcare this morning. Here's $LLY, which continues to set up constructively.
Show more


$SPY $DKNG $LLY $PSKY $VLVLY 1) In a post on Truth Social, President Trump states: "...I will be announcing, in the near future, the AI 'Czar' - Only High I.Q. individuals need apply! AI is the next Industrial Revolution, or Internet, but will be even larger and more impactful, possibly as much as 25% of our Country's GDP. We are leading China, and the rest of the World, and I intend to keep it that way!" 2) DraftKings (DKNG) puts customer betting records into a machine learning model to find out who is most likely to make losing bets, Alex Klavens, Walt Bogdanich and Jenny Vrentas of New York Times report. The company uses data science to target losing gamblers with promotions that encourage more betting, six former employees told the Times. 3) Some emerging scientific research points to an increased risk for GLP-1 patients to develop nonarteritic anterior ischemic optic neuropathy, or vision loss, Alex Janin of Wall Street Journal reports. GLP-1 developers Novo Nordisk (NVO) and Eli Lilly (LLY) face lawsuits from patients claiming the medications caused NAION, the Journal adds. 4) Paramount (PSKY) and states looking to block its acquisition of Warner Bros. (WBD) could settle as soon as this week, Jody Godoy of Reuters reports, citing sources familiar with the matter. A commitment on the number of movie releases is among the terms of the settlement, the sources added. 5) The Board of Directors of Volvo Cars (VLVLY) has appointed Klaus Zellmer as President and Chief Executive Officer. Klaus Zellmer will assume the position no later than 1 October 2027. Hakan Samuelsson will, together with the Board, ensure a seamless transition. Klaus Zellmer most recently served Chairman of the Board of Management and CEO of Skoda Auto, a Volkswagen (VWAGY) company.
Show more
$LLY $NVO Lilly and Novo face lawsuits over GLP-1 vision loss risk, WSJ says. Some emerging scientific research points to an increased risk for GLP-1 patients of developing nonarteritic anterior ischemic optic neuropathy, or vision loss, Alex Janin of the Wall Street Journal reports. GLP-1 developers Novo Nordisk (NVO) and Eli Lilly (LLY) face lawsuits from patients claiming the medications caused NAION, the Journal adds. Evidence of the vision loss risk is mixed and not clear enough to say whether or how the drugs cause the condition, doctors and researchers said, according to the Journal.
Show moreThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.